inking inflammation and hypoxia to disease subtype and course in systemic sclerosis by exploratory analysis of SMAD-linker domains study

Recruiting

• Conditions: systemic sclerosis - scleroderma; 10003816; 10010761

• Registration Number: NL-OMON43179
• Lead Sponsor: reumatologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

-10 patients with limited systemic sclerosis (SSc), 10 with early diffuse SSc, 10 with established diffuse SSc without severe vasculopathy, 10 with established diffuse SSc with severe vasculopathy.
-18 years or older

Exclusion Criteria

active inflammatory or infectious co-morbid disease

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Amount of activated SMAD proteins in fibroblasts</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>effect of SMAD inhibitors on fibroblast activation.<br /><br>activation of other SMAD activating kinases.</p><br>